⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for fludarabine phosphate

Every month we try and update this database with for fludarabine phosphate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaNCT04007029
CD19 Positive
CD20 Positive
Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Mantl...
Recurrent Prima...
Recurrent Small...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Mant...
Refractory Prim...
Refractory Smal...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Tocilizumab
18 Years - 70 YearsJonsson Comprehensive Cancer Center
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesNCT01175785
Accelerated Pha...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Childhood Acute...
Childhood Acute...
Childhood Chron...
Childhood Myelo...
Chronic Phase C...
de Novo Myelody...
Previously Trea...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Relapsing Chron...
Secondary Myelo...
umbilical cord ...
fludarabine pho...
cyclophosphamid...
ex vivo-expande...
total-body irra...
cyclosporine
mycophenolate m...
laboratory biom...
6 Months - 45 YearsNohla Therapeutics, Inc.
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney CancerNCT00004135
Kidney Cancer
Melanoma (Skin)
filgrastim
therapeutic all...
cyclophosphamid...
fludarabine pho...
peripheral bloo...
18 Years - 65 YearsUniversity of Chicago
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic MelanomaNCT00091143
Melanoma (Skin)
gp100 antigen
incomplete Freu...
keyhole limpet ...
fludarabine pho...
peripheral bloo...
18 Years - National Cancer Institute (NCI)
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi AnemiaNCT00453388
Acute Myeloid L...
de Novo Myelody...
Fanconi Anemia
Previously Trea...
Allogeneic Bone...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Nonmyeloablativ...
Total-Body Irra...
- Fred Hutchinson Cancer Center
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin LymphomaNCT00907036
Lymphoma
alemtuzumab
donor lymphocyt...
cyclosporine
fludarabine pho...
melphalan
allogeneic hema...
16 Years - 65 YearsNational Cancer Institute (NCI)
Cord Blood Natural Killer (NK) Cells in Leukemia/LymphomaNCT02280525
Leukemia
Lenalidomide
Rituximab
Fludarabine
Cyclophosphamid...
NK Cells
Cytarabine
18 Years - 80 YearsM.D. Anderson Cancer Center
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell TransplantNCT02333162
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Recurrent Hemat...
Fludarabine Pho...
Melphalan
Intensity-Modul...
Total Marrow Ir...
Allogeneic Hema...
Peripheral Bloo...
Allogeneic Bone...
Tacrolimus
Mycophenolate M...
Laboratory Biom...
18 Years - 75 YearsUniversity of Chicago
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesNCT01823198
Accelerated Pha...
Acute Erythroid...
Acute Megakaryo...
Acute Myeloid L...
Acute Myeloid L...
Acute Myeloid L...
Blast Phase Chr...
Blasts Under 20...
Blasts Under 20...
Chronic Myelomo...
High Risk Myelo...
Myelodysplastic...
Recurrent Chron...
Therapy-Related...
Therapy-Related...
Aldesleukin
Allogeneic CD56...
Allogeneic Hema...
Busulfan
Fludarabine Pho...
Laboratory Biom...
Peripheral Bloo...
Pharmacological...
7 Years - 65 YearsM.D. Anderson Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerNCT00723099
Acute Lymphobla...
Acute Myeloid L...
Aggressive Non-...
Chronic Myeloge...
Chronic Phase C...
Indolent Non-Ho...
Lymphoma
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Recurrent Chron...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Plasm...
Recurrent Small...
Recurrent T-Cel...
Refractory Chro...
Refractory Chro...
Refractory Foll...
Refractory Hodg...
Refractory Lymp...
Refractory Mant...
Refractory Smal...
T-Cell Non-Hodg...
Allogeneic Hema...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Total-Body Irra...
Umbilical Cord ...
- 69 YearsFred Hutchinson Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSNCT01300572
Chronic Myelomo...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Secondary Acute...
Allogeneic Bone...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Indium In 111 A...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Pharmacological...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - Fred Hutchinson Cancer Center
Natural Killer Cell (CYNK-001) Infusions in Adults With AMLNCT04310592
Leukemia
Leukemia, Myelo...
Leukemia, Myelo...
Neoplasms by Hi...
Neoplasms
Immunosuppressi...
Immunologic Fac...
Physiological E...
Alkylating Agen...
Antimetabolites...
Antiviral Agent...
Analgesics, Non...
Anti-infective ...
Analgesics
Peripheral Nerv...
Hematologic Dis...
Hematologic Neo...
Leukemia in Rem...
Relapsed Adult ...
Refractory AML
CYNK-001
18 Years - 80 YearsCelularity Incorporated
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast CancerNCT00020176
Breast Cancer
filgrastim
therapeutic all...
cyclophosphamid...
cyclosporine
fludarabine pho...
peripheral bloo...
18 Years - 70 YearsNational Cancer Institute (NCI)
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell TransplantNCT01640301
Recurrent Adult...
Recurrent Child...
Secondary Acute...
Therapy-Related...
Donor
Hematopoietic C...
HLA-A*0201 Posi...
Recurrent Acute...
Aldesleukin
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
WT1-Sensitized ...
- Fred Hutchinson Cancer Center
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesNCT05418088
Recurrent Acute...
Recurrent B Acu...
Recurrent B-Cel...
Recurrent Chron...
Recurrent High ...
Recurrent Indol...
Recurrent Non-H...
Recurrent Trans...
Refractory Acut...
Refractory B Ac...
Refractory B-Ce...
Refractory Chro...
Refractory High...
Refractory Indo...
Refractory Non-...
Refractory Tran...
Anti-CD19/CD20/...
Cyclophosphamid...
Fludarabine Pho...
18 Years - Ohio State University Comprehensive Cancer Center
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple MyelomaNCT00006184
Multiple Myelom...
Myeloma Immunog...
Bortezomib
Cyclophosphamid...
Cyclosporine
Doxorubicin hyd...
Etoposide
Fludarabine pho...
Prednisone
Vincristine Sul...
Methotrexate
GMCSF (granuloc...
GCSF (granulocy...
18 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaNCT00119392
B-cell Chronic ...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
cyclosporine
fludarabine pho...
mycophenolate m...
yttrium Y 90 ib...
peripheral bloo...
allogeneic hema...
total-body irra...
18 Years - Fred Hutchinson Cancer Center
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid LeukemiaNCT00003145
Accelerated Pha...
Childhood Chron...
Chronic Myeloge...
Chronic Phase o...
Recurrent Disea...
Fludarabine Pho...
Total-Body Irra...
Nonmyeloablativ...
Peripheral Bloo...
Cyclosporine
Mycophenolate M...
Therapeutic All...
Laboratory Biom...
- 74 YearsFred Hutchinson Cancer Center
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete RemissionNCT00070135
Adult Acute Mye...
Acute Myeloid L...
filgrastim
Anti-Thymocyte ...
busulfan
fludarabine pho...
methotrexate
tacrolimus
Allogeneic Hema...
60 Years - 74 YearsAlliance for Clinical Trials in Oncology
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible DonorNCT01598025
Acute Leukemia
Chronic Leukemi...
Myelodysplastic...
Non-Hodgkins Ly...
total-body irra...
thiotepa
fludarabine pho...
melphalan
anti-thymocyte ...
allogeneic hema...
peripheral bloo...
laboratory biom...
- 19 YearsMemorial Sloan Kettering Cancer Center
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaNCT00004862
Leukemia
filgrastim
oblimersen sodi...
cytarabine
fludarabine pho...
16 Years - National Cancer Institute (NCI)
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic LeukemiaNCT00003619
Chronic Myelopr...
Leukemia
Myelodysplastic...
Thrombocytopeni...
filgrastim
vitamin E
busulfan
cytarabine
etoposide
fludarabine pho...
isotretinoin
topotecan hydro...
bone marrow abl...
peripheral bloo...
19 Years - 90 YearsNational Cancer Institute (NCI)
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesNCT02529813
Acute Biphenoty...
Acute Lymphobla...
Blasts 5 Percen...
CD19 Positive
Minimal Residua...
Non-Hodgkin Lym...
Small Lymphocyt...
Stage III Chron...
Stage IV Chroni...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Tisagenlecleuce...
1 Year - 80 YearsM.D. Anderson Cancer Center
Hematopoietic Stem Cell Transplantation in the Treatment of Infant LeukemiaNCT00357565
Leukemia
Myelodysplastic...
Childhood Acute...
Recurrent Child...
Secondary Acute...
Childhood Acute...
Previously Trea...
Secondary Myelo...
Refractory Anem...
Refractory Anem...
Refractory Anem...
De Novo Myelody...
Childhood Myelo...
filgrastim
busulfan
cyclosporine
fludarabine pho...
melphalan
mycophenolate m...
umbilical cord ...
- 3 YearsMasonic Cancer Center, University of Minnesota
Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic LymphomaNCT00045513
Leukemia
Lymphoma
7-hydroxystauro...
fludarabine pho...
18 Years - University Health Network, Toronto
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric SarcomasNCT00043979
Sarcoma
F-18 Fluorodeox...
therapeutic all...
cyclophosphamid...
cyclosporine
doxorubicin hyd...
etoposide
fludarabine pho...
melphalan
prednisone
sirolimus
tacrolimus
vincristine sul...
peripheral bloo...
Filgrastim
Peripheral Bloo...
5 Years - 35 YearsNational Institutes of Health Clinical Center (CC)
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerNCT05400122
Colorectal Canc...
Hematologic Mal...
Rectum Cancer
Acute Myeloid L...
Myelodysplastic...
Acute Lymphobla...
Chronic Myeloid...
Chronic Lymphoc...
Hodgkin Lymphom...
Non Hodgkin Lym...
Myeloproliferat...
Plasma Cell Mye...
Vactosertib
Fludarabine Pho...
Cyclophosphamid...
IL-2
Natural Killer ...
18 Years - Case Comprehensive Cancer Center
Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic LeukemiaNCT00276809
Chronic Lymphoc...
alemtuzumab
filgrastim
carmustine
cyclophosphamid...
cytarabine
dexamethasone
etoposide
fludarabine pho...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - 60 YearsGerman CLL Study Group
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisNCT02528877
Acute Myeloid L...
Primary Myelofi...
Primary Myelofi...
Secondary Acute...
Secondary Myelo...
Allogeneic Bone...
Allogeneic Hema...
Fludarabine Pho...
Laboratory Biom...
Melphalan
Peripheral Bloo...
Pharmacological...
Ruxolitinib Pho...
Sirolimus
Tacrolimus
18 Years - 75 YearsCity of Hope Medical Center
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic MelanomaNCT05470283
Tumor
Metastatic Mela...
Melanoma
OBX-115
Acetazolamide
Cyclophosphamid...
Furosemide
Mesna
Fludarabine Pho...
18 Years - M.D. Anderson Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesNCT00376519
Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
Secondary Myelo...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
Treg cell infus...
umbilical cord ...
total-body irra...
18 Years - 45 YearsMasonic Cancer Center, University of Minnesota
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)NCT01471444
Disorder Relate...
Leukemia
Transplantation...
Fludarabine
Clofarabine
Busulfan
Thymoglobulin
Stem Cell Infus...
Tacrolimus
Methotrexate
3 Years - 70 YearsM.D. Anderson Cancer Center
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesNCT06383572
Lymphodepleting...
Myeloid Maligna...
Cyclophosphamid...
Fludarabine pho...
Decitabine
18 Years - 75 YearsM.D. Anderson Cancer Center
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaNCT00397800
Lymphoma
rituximab
cyclophosphamid...
fludarabine pho...
yttrium Y 90 ib...
50 Years - 75 YearsTechnical University of Munich
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHDNCT00914940
Graft Versus Ho...
Leukemia
Myelodysplastic...
Fludarabine Pho...
Tacrolimus
Thiotepa
Total-Body Irra...
Magnetic Affini...
Peripheral Bloo...
Allogeneic Hema...
T Cell-Depleted...
14 Years - 55 YearsFred Hutchinson Cancer Center
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic MelanomaNCT00062036
Melanoma (Skin)
aldesleukin
filgrastim
incomplete Freu...
interleukin-2 g...
therapeutic tum...
cyclophosphamid...
fludarabine pho...
18 Years - 120 YearsNational Institutes of Health Clinical Center (CC)
Cellular Therapy With Cord Blood CellsNCT00427557
Multiple Myelom...
Leukemia
Lymphoma
Fludarabine
Melphalan
Umbilical Cord ...
Rituximab
Peripheral Bloo...
- 80 YearsM.D. Anderson Cancer Center
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT02057770
Leukemia, Myelo...
busulfan
fludarabine pho...
total-body irra...
Stem cell trans...
cyclophosphamid...
tocilizumab
18 Years - Washington University School of Medicine
Randomized Double Cord Blood Transplant StudyNCT00067002
Leukemia, Lymph...
Leukemia, Myelo...
Leukemia, Myelo...
Lymphoma, Non-H...
Expanded alloge...
One Unmanipulat...
Rituxan
Melphalan
Thiotepa
Fludarabine
Cyclophosphamid...
Mesna
Total body irra...
1 Month - 80 YearsM.D. Anderson Cancer Center
Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT00024440
Leukemia
filgrastim
oblimersen sodi...
cyclophosphamid...
fludarabine pho...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaNCT00278213
Prolymphocytic ...
alemtuzumab
cyclophosphamid...
fludarabine pho...
mitoxantrone hy...
18 Years - 70 YearsGerman CLL Study Group
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)NCT00941928
Leukemia
Pediatric Cance...
Epratuzumab
Fludarabine
Cyclophosphamid...
Mesna
Infusion of NK ...
Interleukin-2
- M.D. Anderson Cancer Center
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationNCT03602898
Acute Lymphobla...
Acute Myeloid L...
Chronic Myelomo...
Chronic Phase C...
Hematopoietic a...
Myelodysplastic...
Myelofibrosis
Myeloproliferat...
Recurrent Acute...
Recurrent Hodgk...
Recurrent Non-H...
Refractory Acut...
Therapy-Related...
Anti-Thymocyte ...
Busulfan
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Methotrexate
Peripheral Bloo...
Quality-of-Life...
Questionnaire A...
Tacrolimus
Total-Body Irra...
- 65 YearsFred Hutchinson Cancer Center
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesNCT06013423
Acute Leukemia ...
Acute Lymphobla...
Acute Myeloid L...
Blastic Plasmac...
Hematopoietic a...
Mixed Phenotype...
Myelodysplastic...
Myeloproliferat...
Non-Hodgkin Lym...
Chronic Myeloid...
Biospecimen Col...
Bone Marrow Asp...
Cyclophosphamid...
Cyclosporine
Diagnostic Imag...
Echocardiograph...
Fludarabine Pho...
Multigated Acqu...
Mycophenolate M...
Survey Administ...
Thiotepa
Total-Body Irra...
Umbilical Cord ...
6 Months - 65 YearsFred Hutchinson Cancer Center
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic LeukemiaNCT01824693
Juvenile Myelom...
Allogeneic Hema...
Busulfan
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Pharmacological...
Tacrolimus
3 Months - 18 YearsChildren's Oncology Group
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic MelanomaNCT00324623
Melanoma (Skin)
Melan-A VLP vac...
adoptive immuno...
therapeutic aut...
cyclophosphamid...
fludarabine pho...
18 Years - 75 YearsCentre Hospitalier Universitaire Vaudois
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT01503242
Plasma Cell Mye...
Refractory Plas...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Mycophenolate M...
Peripheral Bloo...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - 65 YearsFred Hutchinson Cancer Center
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesNCT06383572
Lymphodepleting...
Myeloid Maligna...
Cyclophosphamid...
Fludarabine pho...
Decitabine
18 Years - 75 YearsM.D. Anderson Cancer Center
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in RemissionNCT00101140
Adult Acute Ery...
Adult Acute Mon...
Adult Acute Mye...
anti-thymocyte ...
fludarabine pho...
thiotepa
biological ther...
bone marrow abl...
chemotherapy
non-specific im...
peripheral bloo...
radiation thera...
18 Years - 59 YearsEastern Cooperative Oncology Group
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)NCT02441803
Leukemia
Busulfan
Fludarabine
Clofarabine
Total Body Irra...
Thymoglobulin
Stem Cell Infus...
Cyclophosphamid...
Tacrolimus
Mycophenolate m...
Decitabine
Cytarabine
Idarubicin
18 Years - 60 YearsM.D. Anderson Cancer Center
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT02048813
Anemia
Chronic Lymphoc...
Small Lymphocyt...
Cyclophosphamid...
Fludarabine Pho...
Ibrutinib
Laboratory Biom...
Pharmacogenomic...
Quality-of-Life...
Rituximab
18 Years - 70 YearsNational Cancer Institute (NCI)
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaNCT01256398
Acute Lymphobla...
Adult B Acute L...
Alemtuzumab
Allogeneic Hema...
Autologous Hema...
Cyclophosphamid...
Cytarabine
Dasatinib
Daunorubicin Hy...
Dexamethasone
Etoposide Phosp...
Filgrastim
Fludarabine Pho...
In Vitro-Treate...
Laboratory Biom...
Leucovorin Calc...
Melphalan
Mercaptopurine
Methotrexate
Pegfilgrastim
Pharmacological...
Tacrolimus
Vincristine Sul...
18 Years - National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDSNCT01300572
Chronic Myelomo...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Secondary Acute...
Allogeneic Bone...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Indium In 111 A...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Pharmacological...
Total-Body Irra...
Yttrium Y 90 An...
18 Years - Fred Hutchinson Cancer Center
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesNCT03241940
B Acute Lymphob...
CD19 Positive
Minimal Residua...
Philadelphia Ch...
Recurrent Adult...
Recurrent Child...
Refractory Acut...
Chimeric Antige...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Questionnaire A...
1 Year - 30 YearsStanford University
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic LeukemiaNCT00002838
Leukemia
Filgrastim (G-C...
Cyclophosphamid...
Fludarabine Pho...
Peripheral Bloo...
- 65 YearsM.D. Anderson Cancer Center
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid TumorsNCT05672459
Solid Tumor
Single Injectio...
Fludarabine pho...
Cyclophosphamid...
leukapheresis
18 Years - M.D. Anderson Cancer Center
Fucosylated T Cells for Graft Versus Host Disease (GVHD) PreventionNCT02423915
Leukemia
Lymphoma
Rituximab
Fludarabine
Cyclophosphamid...
Total Body Radi...
Fucosylated Reg...
Cord Blood Infu...
Mycophenolate m...
Sirolimus
Bone Marrow Asp...
G-CSF
Non-Fucosylated...
18 Years - 80 YearsM.D. Anderson Cancer Center
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory LeukemiaNCT05761171
Recurrent Acute...
Recurrent Acute...
Recurrent Acute...
Recurrent Acute...
Recurrent Acute...
Recurrent Mixed...
Refractory Acut...
Refractory Acut...
Refractory Acut...
Refractory Acut...
Refractory Acut...
Refractory Mixe...
Biospecimen Col...
Bone Marrow Asp...
Calaspargase Pe...
Cytarabine
Echocardiograph...
Fludarabine Pho...
Hydrocortisone ...
Lumbar Puncture
Methotrexate
Multigated Acqu...
Prednisolone
Prednisone
Revumenib
Vincristine Sul...
1 Month - 6 YearsChildren's Oncology Group
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic LeukemiaNCT00612612
B-cell Chronic ...
Leukemia
Prolymphocytic ...
Refractory Chro...
Stage I Chronic...
Stage II Chroni...
Stage III Chron...
Stage IV Chroni...
obatoclax mesyl...
fludarabine pho...
rituximab
laboratory biom...
18 Years - National Cancer Institute (NCI)
Safety and Efficacy of Campath in Nonmyeloablative TransplantationNCT00038844
Lymphoma
Leukemia
Campath-1 H (Al...
Fludarabine
Cyclophosphamid...
Rituximab
- 70 YearsM.D. Anderson Cancer Center
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerNCT00027820
Adult Acute Mye...
Childhood Acute...
Childhood Acute...
Childhood Myelo...
Childhood Renal...
Chronic Myelomo...
Clear Cell Rena...
de Novo Myelody...
Metastatic Rena...
Previously Trea...
Progression of ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Refractory Anem...
Refractory Anem...
Refractory Chil...
Refractory Chro...
Renal Medullary...
Type 1 Papillar...
Type 2 Papillar...
Untreated Adult...
Untreated Adult...
Untreated Child...
Fludarabine Pho...
Total-Body Irra...
Peripheral Bloo...
Nonmyeloablativ...
Cyclosporine
Mycophenolate M...
- Fred Hutchinson Cancer Center
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple MyelomaNCT04579523
Plasma Cell Mye...
Recurrent Plasm...
Refractory Plas...
Allogeneic Hema...
Astatine At 211...
Cyclophosphamid...
Fludarabine Pho...
Total-Body Irra...
18 Years - 70 YearsFred Hutchinson Cancer Center
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)NCT01471444
Disorder Relate...
Leukemia
Transplantation...
Fludarabine
Clofarabine
Busulfan
Thymoglobulin
Stem Cell Infus...
Tacrolimus
Methotrexate
3 Years - 70 YearsM.D. Anderson Cancer Center
Cellular Therapy With Cord Blood CellsNCT00427557
Multiple Myelom...
Leukemia
Lymphoma
Fludarabine
Melphalan
Umbilical Cord ...
Rituximab
Peripheral Bloo...
- 80 YearsM.D. Anderson Cancer Center
Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV MelanomaNCT00006233
Melanoma (Skin)
therapeutic all...
cyclosporine
fludarabine pho...
mycophenolate m...
peripheral bloo...
radiation thera...
18 Years - 64 YearsFred Hutchinson Cancer Center
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell SupportNCT00506857
Hematologic Mal...
Busulfan
Fludarabine
- 75 YearsM.D. Anderson Cancer Center
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic LeukemiaNCT00513747
Leukemia
rituximab
fludarabine pho...
18 Years - Alliance for Clinical Trials in Oncology
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemissionNCT00305708
Congenital Ameg...
Diamond-blackfa...
Fanconi Anemia
Leukemia
Severe Congenit...
Thrombocytopeni...
anti-thymocyte ...
busulfan
fludarabine pho...
allogeneic bone...
peripheral bloo...
umbilical cord ...
radiation thera...
- 17 YearsUniversity of California, San Francisco
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantNCT01251575
Adult Acute Lym...
Adult Acute Mye...
Adult Diffuse L...
Adult Myelodysp...
Adult Non-Hodgk...
Aggressive Non-...
Childhood Acute...
Childhood Acute...
Childhood Diffu...
Childhood Myelo...
Childhood Non-H...
Chronic Lymphoc...
Chronic Lymphoc...
Chronic Phase C...
Hematopoietic a...
Mantle Cell Lym...
Plasma Cell Mye...
Prolymphocytic ...
Recurrent Chron...
Refractory Chro...
T-Cell Prolymph...
Waldenstrom Mac...
Recurrent Diffu...
Recurrent Hodgk...
Allogeneic Hema...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Peripheral Bloo...
Sirolimus
Total-Body Irra...
- Fred Hutchinson Cancer Center
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT01707004
Acute Myeloid L...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Secondary Acute...
decitabine
fludarabine pho...
busulfan
cyclophosphamid...
tacrolimus
mycophenolate m...
filgrastim
total-body irra...
allogeneic bone...
laboratory biom...
18 Years - 75 YearsUniversity of Wisconsin, Madison
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell TransplantNCT02333162
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Recurrent Hemat...
Fludarabine Pho...
Melphalan
Intensity-Modul...
Total Marrow Ir...
Allogeneic Hema...
Peripheral Bloo...
Allogeneic Bone...
Tacrolimus
Mycophenolate M...
Laboratory Biom...
18 Years - 75 YearsUniversity of Chicago
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AMLNCT00871689
Leukemia
aldesleukin
cyclophosphamid...
fludarabine pho...
umbilical cord ...
total-body irra...
- 45 YearsMasonic Cancer Center, University of Minnesota
Busulfan and Fludarabine Followed by Post-transplant CyclophosphamideNCT00800839
Hematologic Dis...
Leukemia
Lymphoma
Myeloma
Busulfan
Fludarabine
Cyclophosphamid...
6 Months - 75 YearsM.D. Anderson Cancer Center
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeNCT03813147
Acute Myeloid L...
Recurrent Acute...
Recurrent Myelo...
Refractory Acut...
Refractory Myel...
Azacitidine
Cytarabine
Fludarabine Pho...
Methotrexate
Pevonedistat
Therapeutic Hyd...
1 Month - 21 YearsNational Cancer Institute (NCI)
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHDNCT00914940
Graft Versus Ho...
Leukemia
Myelodysplastic...
Fludarabine Pho...
Tacrolimus
Thiotepa
Total-Body Irra...
Magnetic Affini...
Peripheral Bloo...
Allogeneic Hema...
T Cell-Depleted...
14 Years - 55 YearsFred Hutchinson Cancer Center
Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic LymphomaNCT00608374
Lymphoma
chlorambucil
fludarabine pho...
quality-of-life...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic LeukemiaNCT00003729
Leukemia
cytarabine
fludarabine pho...
idarubicin
- 17 YearsEuropean Organisation for Research and Treatment of Cancer - EORTC
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed LymphomaNCT02652468
Lymphoma
Fludarabine Pho...
Mesna
Cyclophosphamid...
Total nodal irr...
T Cell-Depleted...
Allogeneic Hema...
Peripheral Bloo...
Mycophenolate M...
Tacrolimus
Rituximab
18 Years - 75 YearsUniversity of Wisconsin, Madison
Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)NCT01019317
Leukemia
AML
MDS
CML
Cytarabine
Fludarabine
12 Years - M.D. Anderson Cancer Center
Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast CancerNCT00006261
Breast Cancer
therapeutic all...
cyclophosphamid...
docetaxel
doxorubicin hyd...
fludarabine pho...
peripheral bloo...
18 Years - 60 YearsCase Comprehensive Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: